Sodium–glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report

BACKGROUND: Sodium–glucose cotransporter 2 inhibitors are among the new-generation oral antihyperglycemic agents that have been used in the treatment of type 2 diabetes mellitus. With the recent coronavirus disease 2019 pandemic and rise of cases in the third wave, diagnosis of life-threatening eugl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yii, Edwin Sze Sian, Azli, Athirah Wan, Sitaram, Premela Naidu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724737/
https://www.ncbi.nlm.nih.gov/pubmed/34983625
http://dx.doi.org/10.1186/s13256-021-03232-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724737/
https://www.ncbi.nlm.nih.gov/pubmed/34983625
http://dx.doi.org/10.1186/s13256-021-03232-3

Ejemplares similares